Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 12/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 12/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20758455 | 0.86 | CARM1 (0.47) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28037393 | 0.85 | CARM1 (0.44) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28036949 | 0.85 | CARM1 (0.50) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28036947 | 0.84 | CARM1 (0.49) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28037374 | 0.84 | CARM1 (0.42) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28036953 | 0.83 | CARM1 (0.43) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL28265428 | 0.79 | GRIN2D (0.39) | CARM1PRMT6SIGMAR1PRMT8TMEM97 | |
| SCHEMBL18822846 | 0.78 | HRH3 (0.56) | HRH3CHEK1 | |
| SCHEMBL28036951 | 0.77 | SLC6A4 (0.51) | — | |
| SCHEMBL28823220 | 0.76 | GPR119 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| CN-105153119-B | Pyridine pyrimidinamine compound or pyridine pyridyl amine compound and its application | 广州必贝特医药技术有限公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-105153119-A | Pyridylpyrimidyl amine compounds or pyridylpyridyl amine compounds and application thereof | GUANGZHOU KEQIN NEW MEDICINE DESIGN CO LTD | 2015-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CARM1 871/4885PRMT6 485/4885SIGMAR1 4260/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | CARM1 443/4885PRMT6 249/4885SIGMAR1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.